Xbiome
未知君
Shenzhen clinical-stage, AI-driven microbiome drug developer that also does consumer-facing functional probiotics and strain licensing — the most credible China microbiome bridge to a consumer-health brand like Coolvex.
- Location
- Tsinghua Information Port, Nanshan District · Shenzhen
- Visit window
- From the Nanshan base · Jul 13–31
- Source status
- high confidenceprofiled
Next action
Keep the dossier ready and use the open questions if a visit window opens.
Why now: Visit window · From the Nanshan base · Jul 13–31
What they do
Combines a self-built AI/bioinformatics platform with gut-microbiome data in a 'data-to-drug' pipeline across all major microbial modalities: formulated bacterial consortia (LBP), engineered microbes, microbial-derived molecules and FMT. Runs 10+ programs, 4 clinical-stage (2 in Phase II) across ulcerative colitis, diabetic foot ulcer, acute GvHD and oncology, plus a separate consumer/functional-probiotic line (XF strains) with consumer-brand partnerships.
Why it matters
Peer benchmark for Pure Advance's lead platform (AI-accelerated microbial-resource discovery + biomanufacturing): a working AI/bioinformatics 'data-to-product' engine over a proprietary strain library, plus a receptive license-in/out BD posture. Its consumer functional-probiotic and strain-licensing side is the most credible China microbiome bridge to a consumer-health line like Coolvex, via licensing or co-research rather than agri.
Pure Advance could offer a MENA/GCC commercialization route they do not yet have.
Visit objective & route
Exploratory learning + relationship visit: benchmark the AI-microbiome 'data-to-drug' and strain-licensing model, explore strain/metabolite co-research and a potential MENA/GCC commercialization route; secondary — the consumer functional-probiotic bridge for the Coolvex line. Not a near-term deal.
Approach route
Direct BD — submit the official collaboration application and reach the platform / strain-licensing partnerships team; request a meeting at the Nanshan HQ during the Shenzhen leg.
Talking points
- Is your functional-probiotic / strain-licensing side open to overseas partners?
- Could your AI-microbiome platform screen strains/metabolites for skin-barrier or anti-irritation use?
- Which programs are furthest along, and where are the partnering openings?
- What does early BD with a Saudi founder look like within the visit window?
- Bring: Pure Advance one-pager (AI-accelerated microbial biocontrols), a 3-minute intro pitch, and an NDA template.
Open questions
- Current clinical status of the UC Phase 1b program and any 2025–2026 readouts.
- Whether any 2024–2026 funding / IPO / new round happened — the key unknown for runway and BD appetite.
- Whether a dedicated BD/partnership contact exists beyond the generic inbox.
- How much the AI engine actually drives discovery vs. supporting a conventional microbiome pipeline.
- Any halal / GCC openness — none found, so likely a net-new conversation.
Risks & unknowns
- Center of gravity is regulated human therapeutics, not agri or a fast consumer cycle.
- No public GCC / Saudi / halal footprint found.
- Scale asymmetry — realistic value is access to strains/platform/know-how, not peer co-development.
- Funding momentum uncertain: roughly a 4-year gap since the 2021 Series B, with no fresh capital event surfacing.
Private-pack boundary